Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F van de Werf

Showing results (31-40 of 290) with videos related to

Pageof 29
Sort By:
Bruxelles Medical|January 1, 1973
Long-term anticoagulant treatment after myocardial infarction. A reviewH de Geest, F Van De Werf
BMJ (Clinical Research Ed.)|November 26, 1988
Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarctionF Van de Werf, A E Arnold
Annals of Internal Medicine|March 1, 1986
Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarctionF Van de Werf, M Nobuhara, D Collen
Acta Cardiologica|December 5, 2000
A case report of a patient with a large aneurysmatic coronary artery fistulaW Anné, J Bogaert, F Van de Werf
Pacing and Clinical Electrophysiology : PACE|February 25, 1998
Prospective evaluation of the length of the lower common pathway in the differential diagnosis of various forms of AV nodal reentrant tachycardiaH Heidbüchel, H Ector, F Van de Werf
Acta Cardiologica|January 1, 1982
Reproducibility of exercise-induced ventricular premature beatsR Stroobandt, F Van de Werf, H Kesteloot
Haemostasis|October 1, 1996
Fibrin-selective thrombolytic therapy with recombinant staphylokinaseD Collen, S Vanderschueren, F Van de Werf
Thrombosis and Haemostasis|October 1, 1996
A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysisS Vanderschueren, D Collen, F van de Werf
JAMA|May 18, 1999
Malondialdehyde-modified LDL as a marker of acute coronary syndromesP Holvoet, D Collen, F Van de Werf
European Heart Journal|May 6, 1998
Survival analysis and classification of death in patients under anti-arrhythmic treatmentH Ector, H Heidbüchel, F Van De Werf
Pageof 29

Showing results (31-40 of 290) with videos related to

Sort By:
Pageof 29
Bruxelles Medical|January 1, 1973
Long-term anticoagulant treatment after myocardial infarction. A reviewH de Geest, F Van De Werf
BMJ (Clinical Research Ed.)|November 26, 1988
Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarctionF Van de Werf, A E Arnold
Annals of Internal Medicine|March 1, 1986
Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarctionF Van de Werf, M Nobuhara, D Collen
Acta Cardiologica|December 5, 2000
A case report of a patient with a large aneurysmatic coronary artery fistulaW Anné, J Bogaert, F Van de Werf
Pacing and Clinical Electrophysiology : PACE|February 25, 1998
Prospective evaluation of the length of the lower common pathway in the differential diagnosis of various forms of AV nodal reentrant tachycardiaH Heidbüchel, H Ector, F Van de Werf
Acta Cardiologica|January 1, 1982
Reproducibility of exercise-induced ventricular premature beatsR Stroobandt, F Van de Werf, H Kesteloot
Haemostasis|October 1, 1996
Fibrin-selective thrombolytic therapy with recombinant staphylokinaseD Collen, S Vanderschueren, F Van de Werf
Thrombosis and Haemostasis|October 1, 1996
A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysisS Vanderschueren, D Collen, F van de Werf
JAMA|May 18, 1999
Malondialdehyde-modified LDL as a marker of acute coronary syndromesP Holvoet, D Collen, F Van de Werf
European Heart Journal|May 6, 1998
Survival analysis and classification of death in patients under anti-arrhythmic treatmentH Ector, H Heidbüchel, F Van De Werf
Pageof 29